321 related articles for article (PubMed ID: 25541698)
1. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
3. Bladder cancer biomarker screening based on non-targeted urine metabolomics.
Li J; Cheng B; Xie H; Zhan C; Li S; Bai P
Int Urol Nephrol; 2022 Jan; 54(1):23-29. PubMed ID: 34850327
[TBL] [Abstract][Full Text] [Related]
4. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
[TBL] [Abstract][Full Text] [Related]
5. Bladder cancer recurrence surveillance by urine metabolomics analysis.
Loras A; Trassierra M; Sanjuan-Herráez D; Martínez-Bisbal MC; Castell JV; Quintás G; Ruiz-Cerdá JL
Sci Rep; 2018 Jun; 8(1):9172. PubMed ID: 29907864
[TBL] [Abstract][Full Text] [Related]
6. Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
Huttanus HM; Vu T; Guruli G; Tracey A; Carswell W; Said N; Du P; Parkinson BG; Orlando G; Robertson JL; Senger RS
PLoS One; 2020; 15(8):e0237070. PubMed ID: 32822394
[TBL] [Abstract][Full Text] [Related]
7. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.
Shkolyar E; Zhao Q; Mach KE; Teslovich NC; Lee TJ; Cox S; Skinner EC; Lu Y; Liao JC
Urol Oncol; 2021 Aug; 39(8):497.e9-497.e15. PubMed ID: 33766467
[TBL] [Abstract][Full Text] [Related]
8. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
9. A microRNA biomarker panel for the non-invasive detection of bladder cancer.
Urquidi V; Netherton M; Gomes-Giacoia E; Serie DJ; Eckel-Passow J; Rosser CJ; Goodison S
Oncotarget; 2016 Dec; 7(52):86290-86299. PubMed ID: 27863434
[TBL] [Abstract][Full Text] [Related]
10. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
11. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
[TBL] [Abstract][Full Text] [Related]
12. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry.
Issaq HJ; Nativ O; Waybright T; Luke B; Veenstra TD; Issaq EJ; Kravstov A; Mullerad M
J Urol; 2008 Jun; 179(6):2422-6. PubMed ID: 18433783
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression.
Putluri N; Shojaie A; Vasu VT; Vareed SK; Nalluri S; Putluri V; Thangjam GS; Panzitt K; Tallman CT; Butler C; Sana TR; Fischer SM; Sica G; Brat DJ; Shi H; Palapattu GS; Lotan Y; Weizer AZ; Terris MK; Shariat SF; Michailidis G; Sreekumar A
Cancer Res; 2011 Dec; 71(24):7376-86. PubMed ID: 21990318
[TBL] [Abstract][Full Text] [Related]
14. Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Nieczaj A; Ruman T
Sci Rep; 2023 Jun; 13(1):9802. PubMed ID: 37328580
[TBL] [Abstract][Full Text] [Related]
15. Recognition of early and late stages of bladder cancer using metabolites and machine learning.
Kouznetsova VL; Kim E; Romm EL; Zhu A; Tsigelny IF
Metabolomics; 2019 Jun; 15(7):94. PubMed ID: 31222577
[TBL] [Abstract][Full Text] [Related]
16. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
17. Urinary mRNA biomarker panel for the detection of urothelial carcinoma.
Urquidi V; Netherton M; Gomes-Giacoia E; Serie D; Eckel-Passow J; Rosser CJ; Goodison S
Oncotarget; 2016 Jun; 7(25):38731-38740. PubMed ID: 27231851
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.
Frantzi M; van Kessel KE; Zwarthoff EC; Marquez M; Rava M; Malats N; Merseburger AS; Katafigiotis I; Stravodimos K; Mullen W; Zoidakis J; Makridakis M; Pejchinovski M; Critselis E; Lichtinghagen R; Brand K; Dakna M; Roubelakis MG; Theodorescu D; Vlahou A; Mischak H; Anagnou NP
Clin Cancer Res; 2016 Aug; 22(16):4077-86. PubMed ID: 27026199
[TBL] [Abstract][Full Text] [Related]
19. Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Ruman T
Sci Rep; 2022 Sep; 12(1):15156. PubMed ID: 36071106
[TBL] [Abstract][Full Text] [Related]
20. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
